- Home
- Products
- Customized ADCs
- CD19
- Anti-CD19 (clone hBU12)-Mc-MMAE ADC
Anti-CD19 (clone hBU12)-Mc-MMAE ADC (CAT#: ADC-W-323)
This ADC product is comprised of an anti-CD19 monoclonal antibody (clone hBU12) conjugated via a Mc linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- Product Information
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Antibody clone #
- hBU12
- Name
- CD19
- Alternative Names
- CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4;
- Target Entrez Gene ID
- 930
- Target UniProt ID
- P15391
- Overview
- Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
- Overview
- Humanized Anti-CD19 lgG1κ antibody, clone # Hbu12
- Clone #
- hBU12
- Species Reactivity
- Human
- Name
- Mc (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAE (Monomethyl auristatin E)
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD3D (Teplizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-833)
- Anti-TNFRSF10B (Tigatuzumab)-SMCC-DM1 ADC (CAT#: ADC-W-1880)
- Anti-CD40 (Lucatumumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-912)
- Anti-PVRL4 (Enfortumab vedotin)-SMCC-DM1 ADC (CAT#: ADC-W-2396)
- Anti-EPCAM (Tucotuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1086)
- Anti-ERBB2 (trastuzumab)-Aminocapropyl-VC-PABC-MMAE ADC (CAT#: ADC-W-630)
- Anti-TNFRSF8 (Brentuximab )-MC-MMAF ADC (CAT#: ADC-W-2345)
- Anti-CD3E (Foralumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-839)
- Anti-CD79b (SN8)-Mc-MMAF ADC (CAT#: ADC-W-225)
- Anti-TAG-72 (Satumomab Pendetide)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2160)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-323. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2520 | Anti-CD19 (Denintuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-778 | Anti-CD19 (Blinatumomab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-493 | Anti-CD19 (clone huB4)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-775 | Anti-CD19 (Taplitumomab paptox)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2519 | Anti-CD19 (Denintuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
CAT# | Product Name | Linker | Payload |
ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-518 | Anti-TM4SF1 ( clone 2A7A)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
ADC-W-515 | Anti-EGFR (ABT-806)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
CAT# | Product Name | Linker | Payload |
ADC-W-465 | Anti-TNFRSF8 (Brentuximab)-VC-PAB-MMAE ADC | VC-PAB (valine-citrulline with PAB) | MMAE (Monomethyl auristatin E) |
ADC-W-529 | Anti-F3 (TF-011)-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
ADC-AA-056 | Anti-MIgG (clone 187.1)-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
ADC-W-565 | Anti-EDNRB-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
ADC-AA-029 | anti-MIgG(Fc)Fab-C-MMAE ADC | Cleavable linkers | MMAE (Monomethyl auristatin E) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.